On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

Iovance Biotherapeutics ( IOVA -1.52%) and CRISPR Therapeutics ( CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

Crispr Therapeutics and Vertex have received regulatory approvals for Casgevy in several geographies, including the European Union, the United Kingdom, and in the United States. We think Casgevy's ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...